AVIR:NSD-Atea Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 71.82

Change

-1.95 (-2.64)%

Market Cap

USD 5.93B

Volume

0.49M

Average Target Price

USD 66.00 (-8.10%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. It also develops AT-787 which is under phase 2 clinical for the treatment of hepatitis C virus; AT-752 which is under phase 2 clinical trial for the treatment of dengue; and AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. The company was incorporated in 2012 and is based in Boston, Massachusetts. Address: 125 Summer Street, Boston, MA, United States, 02110

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-10.59 (-6.73%)

USD62.28B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.68 (+0.80%)

USD54.69B 20.45 15.08
REGN Regeneron Pharmaceuticals, Inc

-8.19 (-1.77%)

USD49.61B 15.17 11.55
ALXN Alexion Pharmaceuticals, Inc

-1.60 (-1.05%)

USD33.27B 55.63 33.22
RPRX Royalty Pharma plc

-1.08 (-2.25%)

USD29.16B 22.60 14.17
BGNE BeiGene, Ltd

-12.93 (-4.05%)

USD29.03B N/A N/A
SGEN Seagen Inc

+1.16 (+0.76%)

USD27.64B 45.27 37.70
BNTX BioNTech SE

-5.23 (-4.75%)

USD25.28B -99,999.99 N/A
GMAB Genmab A/S

-1.29 (-3.67%)

USD22.05B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing AVIR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 108.29% 95% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 108.29% 95% A 95% A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 4,360.87% 97% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 4,360.87% 97% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain -7.11% 30% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.11% 30% F 18% F
Risk Return Profile  
Volatility (Standard Deviation) 42.39% 66% D 34% F
Risk Adjusted Return -16.78% 28% F 24% F
Market Capitalization 5.93B 92% A- 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 21.84 11% F 8% F
Price / Cash Flow Ratio -463.05 99% A+ 98% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 34.08% 93% A 95% A
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.17 27% F 15% F
Short Percent 2.19% 80% B- 61% D-
Beta -0.61 98% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.